{"meta":{"query_hash":"6ac19511148b","filters":{"venue":"Section 4: Clinical pharmacy services"},"cohort_total":13,"direct_labels_cover":0,"predictions_cover":13,"exported":13,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6ac19511148b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Section+4%3A+Clinical+pharmacy+services"},"results":[{"id":"W2921353678","doi":"10.1136/ejhpharm-2019-eahpconf.269","title":"4CPS-120 Erlotinib in non-small-cell lung cancer without epidermal growth factor receptor activating mutations","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Epidermal growth factor receptor; Oncology; Lung cancer; Chemotherapy; Taxane; Erlotinib Hydrochloride; Adverse effect; Cancer; Breast cancer","score_opus":0.038105665510673306,"score_gpt":0.4265117572884367,"score_spread":0.3884060917777634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921353678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952377,0.0021698861,0.000119448545,0.0000920381,0.000019052168,0.00009861082,0.000940706,0.000015308964,0.0013072392],"genre_scores_gemma":[0.9974081,0.00076738425,0.00015654271,0.000111644746,0.000029338311,0.00005881088,0.001063317,0.0000042466163,0.00040054298],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997061,0.00009995438,0.000051110164,0.00003160316,0.000056610977,0.000054622444],"domain_scores_gemma":[0.9995041,0.00010355688,0.00019445138,0.000036359408,0.000047937512,0.00011362451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000600258,0.00014003784,0.00039759194,0.00029069526,0.00020979067,0.0003455224,0.00017427294,0.00030742108,0.0027957696],"category_scores_gemma":[0.000570191,0.000085999585,0.0005306053,0.00054119003,0.00020586622,0.00019692046,0.0002223133,0.0002719072,0.0006055702],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035530925,0.0019111132,0.80367935,0.0011761099,0.0004111246,0.0026773715,0.00017754792,0.00067036436,0.014533535,0.00019373777,0.0048013935,0.13423744],"study_design_scores_gemma":[0.0035913587,0.025517825,0.9409249,0.0002294084,0.00041809684,0.008193136,0.00020049278,0.0012466256,0.006795536,0.00019005353,0.012673668,0.000018945082],"about_ca_topic_score_codex":0.001463682,"about_ca_topic_score_gemma":0.0025882698,"teacher_disagreement_score":0.0027957696,"about_ca_system_score_codex":0.00041588533,"about_ca_system_score_gemma":0.00070938334,"threshold_uncertainty_score":0.009352744},"labels":[],"label_agreement":null},{"id":"W2944589946","doi":"10.1136/ejhpharm-2019-eahpconf.403","title":"4CPS-254 Biosimilar rituximab – a year beyond","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Kidney Foundation of Canada","keywords":"Biosimilar; Rituximab; Medicine; Discontinuation; Rheumatoid arthritis; Pharmacy; Retrospective cohort study; Internal medicine; Oncology; Lymphoma; Family medicine","score_opus":0.034963637577777165,"score_gpt":0.3810492240157845,"score_spread":0.34608558643800735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944589946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5483142,0.069195315,0.007478002,0.06588458,0.015379059,0.001179925,0.027397176,0.0015490487,0.26362258],"genre_scores_gemma":[0.8097158,0.014384557,0.005469346,0.03050036,0.0063851234,0.0003665404,0.02642331,0.00037380183,0.10638106],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99827766,0.00035711288,0.00018692443,0.00017481176,0.00075891655,0.00024453425],"domain_scores_gemma":[0.9964461,0.00051384297,0.00076798396,0.00032768812,0.0010693175,0.00087515643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028536739,0.00021502936,0.0002851325,0.00061794784,0.0005213507,0.001514294,0.00046135005,0.0013061434,0.033243433],"category_scores_gemma":[0.0042093275,0.0001093893,0.00054951897,0.00069584325,0.0004679278,0.0008637526,0.00083164906,0.0014020015,0.010863564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059723263,0.0013355928,0.0838408,0.0010047966,0.0002766961,0.005593663,0.00040866,0.0006077723,0.015916543,0.0077837864,0.3062259,0.57103354],"study_design_scores_gemma":[0.00037770087,0.0021100282,0.05712342,0.0005176091,0.00008207264,0.005753341,0.00028399343,0.00047610863,0.006690073,0.0014002101,0.92515206,0.000033368382],"about_ca_topic_score_codex":0.002425318,"about_ca_topic_score_gemma":0.0019134015,"teacher_disagreement_score":0.033243433,"about_ca_system_score_codex":0.0016905328,"about_ca_system_score_gemma":0.0019241708,"threshold_uncertainty_score":0.111210406},"labels":[],"label_agreement":null},{"id":"W2945528492","doi":"10.1136/ejhpharm-2019-eahpconf.404","title":"4CPS-255 The effect of an enhancing medication adherence programme for a type 2 diabetes mellitus network","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chulabhorn Research Institute; Copperbelt University; Kidney Foundation of Canada","keywords":"Medicine; Pharmacist; Pharmacy; Test (biology); Family medicine; Type 2 Diabetes Mellitus; Diabetes mellitus","score_opus":0.07543680084374962,"score_gpt":0.4363149610199399,"score_spread":0.36087816017619023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945528492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9198978,0.0017042625,0.00042295922,0.013549056,0.0021897608,0.0089907,0.0035965047,0.00029069924,0.049358167],"genre_scores_gemma":[0.92678845,0.0030951775,0.0069619818,0.008909794,0.001979938,0.010517106,0.003678046,0.000060709583,0.038008742],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99889755,0.00066971884,0.000047590027,0.00006771193,0.00012257518,0.00019480934],"domain_scores_gemma":[0.99588424,0.0004673452,0.00022064017,0.00015014973,0.00026556753,0.0030119533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018053125,0.00025777184,0.00038394035,0.00033485016,0.0010153058,0.00062126905,0.000628855,0.0008681443,0.030617025],"category_scores_gemma":[0.00365595,0.00016942159,0.00087898626,0.0002820978,0.0001901167,0.00050129683,0.0015124694,0.001237265,0.0017458659],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020988524,0.0931367,0.06179557,0.0021941937,0.00042986518,0.00047250238,0.0009977019,0.0006890208,0.0013683769,0.0006478513,0.07202991,0.7452498],"study_design_scores_gemma":[0.03218393,0.10007943,0.76169235,0.0026269788,0.0006929515,0.0003831664,0.002529459,0.0017925205,0.0010346316,0.00047319563,0.096445665,0.000065745306],"about_ca_topic_score_codex":0.011490652,"about_ca_topic_score_gemma":0.015749803,"teacher_disagreement_score":0.030617025,"about_ca_system_score_codex":0.00095202436,"about_ca_system_score_gemma":0.0038970895,"threshold_uncertainty_score":0.102424145},"labels":[],"label_agreement":null},{"id":"W3016600733","doi":"10.1136/ejhpharm-2020-eahpconf.281","title":"4CPS-180 From evidence based medicine to practice: gum chewing for postoperative recovery of gastrointestinal function after colorectal surgery with interprofessional teamwork","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Enhanced Recovery After Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; University Hospital Southampton NHS Foundation Trust","keywords":"Medicine; Randomized controlled trial; Colorectal surgery; Teamwork; Defecation; Colostomy; Physical therapy; Surgery; Abdominal surgery","score_opus":0.0752212007927984,"score_gpt":0.3995477239843968,"score_spread":0.3243265231915984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016600733","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005727086,0.87056035,0.002348937,0.063966215,0.011797656,0.0059291455,0.0018916796,0.00019942777,0.03757951],"genre_scores_gemma":[0.059863918,0.861005,0.019743174,0.040581714,0.006266836,0.0060577556,0.0021219829,0.00008414086,0.004275455],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98088914,0.009295868,0.0059704627,0.0005064503,0.0029945222,0.00034356734],"domain_scores_gemma":[0.9633601,0.018479574,0.00765197,0.001076068,0.007591615,0.0018406599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014472051,0.0010696398,0.00212203,0.007694511,0.0012730458,0.004576459,0.0018263281,0.005315219,0.03265403],"category_scores_gemma":[0.06126826,0.0007590229,0.0054300246,0.005850141,0.0013643522,0.0039783926,0.003470275,0.0033913753,0.004321296],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094272644,0.00046536172,0.0016815047,0.3810771,0.0017616531,0.00031384325,0.0005420155,0.00021841069,0.00053651986,0.0030314228,0.06017291,0.54925656],"study_design_scores_gemma":[0.0021629706,0.0010277937,0.010087452,0.8110643,0.003847264,0.000794719,0.0007065432,0.0002230015,0.000492326,0.004774817,0.16475023,0.000068653826],"about_ca_topic_score_codex":0.003029616,"about_ca_topic_score_gemma":0.0064211446,"teacher_disagreement_score":0.03265403,"about_ca_system_score_codex":0.0047000763,"about_ca_system_score_gemma":0.016332597,"threshold_uncertainty_score":0.109238565},"labels":[],"label_agreement":null},{"id":"W3016926053","doi":"10.1136/ejhpharm-2020-eahpconf.280","title":"4CPS-179 The wide review of polypharmacy in the frail older person","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; University Hospital Southampton NHS Foundation Trust","keywords":"Polypharmacy; Computer science; Older people; Gerontology; Medicine; Intensive care medicine","score_opus":0.2952603473552379,"score_gpt":0.5051458419799638,"score_spread":0.20988549462472594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016926053","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45869327,0.13717856,0.004039727,0.1568435,0.00876755,0.009044091,0.020282915,0.00070166605,0.2044488],"genre_scores_gemma":[0.8545245,0.06295619,0.011413151,0.027711587,0.005807754,0.0046875677,0.0049845865,0.00015391372,0.027760731],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99275935,0.0044408445,0.0009730303,0.0002536052,0.0012378551,0.0003352026],"domain_scores_gemma":[0.9669192,0.009969233,0.0063139345,0.001704963,0.007517196,0.007575493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074064136,0.00020393037,0.00047564547,0.0022800777,0.001109937,0.0021457523,0.000565322,0.0011101194,0.022950875],"category_scores_gemma":[0.036683053,0.00025762,0.00072184374,0.0024618134,0.0008208346,0.0014556339,0.0023932594,0.0007165007,0.0026459112],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012522507,0.0012380239,0.13434401,0.01152364,0.00045285572,0.00077193155,0.0022267425,0.0002977677,0.001032312,0.0027446665,0.2858974,0.5582184],"study_design_scores_gemma":[0.0008483163,0.003841258,0.51735574,0.017733691,0.0005029898,0.0025528225,0.0041460157,0.00061129854,0.0008425302,0.0022991393,0.4491897,0.000076448836],"about_ca_topic_score_codex":0.009856039,"about_ca_topic_score_gemma":0.021273393,"teacher_disagreement_score":0.022950875,"about_ca_system_score_codex":0.0028796387,"about_ca_system_score_gemma":0.01431403,"threshold_uncertainty_score":0.07677835},"labels":[],"label_agreement":null},{"id":"W3016962124","doi":"10.1136/ejhpharm-2020-eahpconf.198","title":"4CPS-097 Secondline treatment of metastatic non-small cell lung cancer with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Rio Tinto","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Lung cancer; Nivolumab; Atezolizumab; Chemotherapy; Performance status; Retrospective cohort study; Cancer; Adverse effect; Immunotherapy","score_opus":0.05666603131101178,"score_gpt":0.38195838794369497,"score_spread":0.3252923566326832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016962124","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4850872,0.42034313,0.002426339,0.01083951,0.004700363,0.006859266,0.008909286,0.00041648213,0.060418446],"genre_scores_gemma":[0.90702873,0.06677804,0.0026816009,0.005676565,0.00088559574,0.0031318476,0.0038070113,0.000038147562,0.00997252],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874854,0.0006952782,0.00018236662,0.00012386503,0.00016882313,0.00008112151],"domain_scores_gemma":[0.9989643,0.00043127313,0.00023682659,0.000053633816,0.00018201626,0.00013194415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018586534,0.00040670685,0.0012461548,0.00062612916,0.0003322566,0.00069307483,0.0003972228,0.00092910376,0.014198152],"category_scores_gemma":[0.0026265113,0.00018138731,0.0028697036,0.0006232027,0.00035394912,0.00066856534,0.0004195853,0.0017221,0.0012557942],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0873738,0.0029838395,0.0065691,0.04938037,0.009459468,0.0002225305,0.00015881471,0.0009634386,0.006493407,0.0014767929,0.023117324,0.811801],"study_design_scores_gemma":[0.40377852,0.18632418,0.06957273,0.031350367,0.020121034,0.0024558215,0.00051492796,0.002048798,0.011617741,0.0025192318,0.26955155,0.00014505717],"about_ca_topic_score_codex":0.0011487106,"about_ca_topic_score_gemma":0.0054373383,"teacher_disagreement_score":0.014198152,"about_ca_system_score_codex":0.00085135794,"about_ca_system_score_gemma":0.0011033582,"threshold_uncertainty_score":0.04749757},"labels":[],"label_agreement":null},{"id":"W3137967144","doi":"10.1136/ejhpharm-2021-eahpconf.232","title":"4CPS-400 The role and value of a ward based pharmacist in the intensive care unit: the critical care physicians’ and nurses’ perceptions","year":2021,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Likert scale; Pharmacist; Intensive care unit; Medicine; Scale (ratio); Nursing; Clinical pharmacy; Critical care nursing; Family medicine; Pharmacy; Psychology; Health care; Intensive care medicine","score_opus":0.1463255160144417,"score_gpt":0.5062585645855626,"score_spread":0.35993304857112096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137967144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9097053,0.001160736,0.0008665343,0.032385852,0.0010934107,0.00020417871,0.0005523429,0.00004456189,0.053987037],"genre_scores_gemma":[0.98387676,0.001179036,0.00076036825,0.005017376,0.00033744983,0.00017068986,0.00023409411,0.000025199528,0.008399038],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9971933,0.0013950092,0.00020282087,0.00008358234,0.00082393986,0.0003014463],"domain_scores_gemma":[0.98862237,0.0050350535,0.0011236685,0.00019617853,0.0025393986,0.0024834564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003376818,0.00018314851,0.00018904316,0.0005351058,0.002434206,0.0028513463,0.0005065804,0.0016794323,0.018555963],"category_scores_gemma":[0.011234365,0.00015937518,0.0003146182,0.0007892009,0.002029534,0.0016827048,0.001778831,0.0016265406,0.0022832842],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031061965,0.0010149301,0.3971578,0.0026187787,0.0000623084,0.0057927496,0.3285681,0.0003395784,0.005382694,0.006454916,0.12355315,0.12874445],"study_design_scores_gemma":[0.000017378772,0.0006436061,0.32449678,0.0012627656,0.00001951579,0.0021787495,0.59524155,0.00030045316,0.00076758274,0.0008228457,0.074197814,0.00005102949],"about_ca_topic_score_codex":0.008611716,"about_ca_topic_score_gemma":0.009837716,"teacher_disagreement_score":0.018555963,"about_ca_system_score_codex":0.0018971189,"about_ca_system_score_gemma":0.0044247094,"threshold_uncertainty_score":0.062075913},"labels":[],"label_agreement":null},{"id":"W3138660907","doi":"10.1136/ejhpharm-2021-eahpconf.178","title":"4CPS-346 Evaluation of the implementation of ‘inhaler interviews’ during medication reconciliation in the pneumology service","year":2021,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Société de Pneumologie de Langue Française","keywords":"Inhaler; Checklist; Medicine; Pharmacy; Medical emergency; Physical therapy; Emergency medicine; Asthma; Nursing; Psychology; Internal medicine","score_opus":0.12528372128493975,"score_gpt":0.4758899914348665,"score_spread":0.35060627014992674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138660907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96986336,0.00023183326,0.0043554655,0.0024350476,0.00031527336,0.011615638,0.00082650594,0.00047534856,0.009881539],"genre_scores_gemma":[0.95243406,0.0003916021,0.028906314,0.0014689765,0.00015487181,0.012312294,0.00076284574,0.000109261564,0.0034596326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.94081485,0.05043059,0.0024598034,0.00089840265,0.0030037025,0.0023927127],"domain_scores_gemma":[0.9288466,0.035622522,0.004846315,0.0031360216,0.015115805,0.012432753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05015971,0.00080651965,0.000726256,0.0010951427,0.0033222763,0.0021048756,0.002228293,0.0014226184,0.007983352],"category_scores_gemma":[0.08226667,0.0008223174,0.0010689099,0.00092079694,0.0011287035,0.0014571034,0.0041905134,0.0016086019,0.0017628847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009650001,0.023557205,0.17671582,0.0065853936,0.00031297488,0.0039847847,0.23947483,0.004104032,0.008902711,0.00085300155,0.022001248,0.5038581],"study_design_scores_gemma":[0.004703328,0.08933024,0.5216856,0.004936822,0.0005630411,0.0017653897,0.24319768,0.012367294,0.011097945,0.0006619805,0.109030485,0.0006602535],"about_ca_topic_score_codex":0.015003426,"about_ca_topic_score_gemma":0.018894957,"teacher_disagreement_score":0.05015971,"about_ca_system_score_codex":0.0063279266,"about_ca_system_score_gemma":0.016247435,"threshold_uncertainty_score":0.26527303},"labels":[],"label_agreement":null},{"id":"W4293230230","doi":"10.1136/ejhpharm-2022-eahp.129","title":"4CPS-099 Clinically relevant drug–drug interaction events in patients with abiraterone, enzalutamide or apalutamide treatment","year":2022,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Rio Tinto","keywords":"Enzalutamide; Medicine; Pharmacology; Prostate cancer; Drug interaction; Internal medicine; Drug; Cancer; Androgen receptor","score_opus":0.05257616929045679,"score_gpt":0.41697915321367546,"score_spread":0.3644029839232187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293230230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8982599,0.01721342,0.001314032,0.0048864395,0.0005186113,0.0010043894,0.03319405,0.00031727998,0.043291908],"genre_scores_gemma":[0.981136,0.0028283685,0.00093080336,0.001472669,0.00028814425,0.00022759679,0.010089764,0.000032776483,0.0029937485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984524,0.00045769772,0.0003767167,0.00014357542,0.00040545515,0.00016417733],"domain_scores_gemma":[0.99612135,0.00093781383,0.0016216415,0.00015144396,0.00047002596,0.00069776195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085677416,0.00024958732,0.0005410549,0.0010478402,0.00072791724,0.00091668876,0.0002870538,0.0008795714,0.013580394],"category_scores_gemma":[0.0042450144,0.00017554058,0.0008705835,0.0016044376,0.00026376464,0.0003639594,0.00086672185,0.000686158,0.0018353768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004434343,0.00034579812,0.8882746,0.0015239057,0.00032173516,0.011048478,0.00039429872,0.00029854983,0.0015493621,0.00042639064,0.026915796,0.064466596],"study_design_scores_gemma":[0.00044851706,0.0012620308,0.9253725,0.00093830534,0.00027154686,0.019804068,0.0005221126,0.0008314629,0.001157899,0.00044871497,0.04889413,0.000048738217],"about_ca_topic_score_codex":0.007727457,"about_ca_topic_score_gemma":0.008125573,"teacher_disagreement_score":0.013580394,"about_ca_system_score_codex":0.0009200006,"about_ca_system_score_gemma":0.0020649268,"threshold_uncertainty_score":0.0454309},"labels":[],"label_agreement":null},{"id":"W4293230261","doi":"10.1136/ejhpharm-2022-eahp.128","title":"4CPS-097 Role of the pharmacist in the care of the lung transplant patient","year":2022,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Transplantation: Methods and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Rio Tinto","keywords":"Medicine; Pharmacist; Lung transplantation; Bronchiectasis; Cystic fibrosis; Lung; Transplantation; Pulmonary function testing; Obstructive lung disease; Multidisciplinary team; Internal medicine; Physical therapy; Intensive care medicine; Pediatrics; COPD; Pharmacy; Family medicine; Nursing","score_opus":0.041331340812046626,"score_gpt":0.408605612208214,"score_spread":0.36727427139616736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293230261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5888271,0.021392647,0.001731622,0.1650951,0.0049648555,0.0006706052,0.0026974226,0.0007166105,0.21390408],"genre_scores_gemma":[0.9359785,0.010096528,0.003646527,0.020811522,0.0041594417,0.0001971491,0.0008533797,0.00008591592,0.024170978],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937695,0.0003117537,0.00005972664,0.000050074814,0.00008933512,0.00011224043],"domain_scores_gemma":[0.9958674,0.00057233917,0.00038403276,0.00007516827,0.0004352097,0.0026658173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008005732,0.0001256629,0.0001903358,0.00042203732,0.0009463951,0.00094607007,0.00031649694,0.001156928,0.036346808],"category_scores_gemma":[0.0028859577,0.00012054913,0.00020710322,0.00040954442,0.000265694,0.00056290947,0.00087458896,0.0009859853,0.004576294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007604874,0.0013594701,0.33741903,0.00081044156,0.0000746471,0.008515061,0.001014209,0.00029028425,0.0014096443,0.000716689,0.17885183,0.46877822],"study_design_scores_gemma":[0.00048777735,0.0032788697,0.63455325,0.0027244044,0.00011402148,0.026319945,0.0066514807,0.0013996101,0.0012414656,0.0010010197,0.32213792,0.000090241],"about_ca_topic_score_codex":0.003391027,"about_ca_topic_score_gemma":0.00537994,"teacher_disagreement_score":0.036346808,"about_ca_system_score_codex":0.0007926815,"about_ca_system_score_gemma":0.0025828995,"threshold_uncertainty_score":0.12159222},"labels":[],"label_agreement":null},{"id":"W4360614867","doi":"10.1136/ejhpharm-2023-eahp.52","title":"4CPS-003 Experiences with a best possible medication history (BPMH) conducted by pharmacy students in the hospital setting: a scoping review","year":2023,"lang":"en","type":"review","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Patient safety; Medicine; Health care; Hospital pharmacy; MEDLINE; Clinical pharmacy; Family medicine; Medical education; Medical emergency","score_opus":0.37382453718878483,"score_gpt":0.5799558731640854,"score_spread":0.20613133597530053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360614867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009684573,0.94688064,0.0011648856,0.00830108,0.0025236725,0.012795377,0.004881208,0.00009330356,0.013675194],"genre_scores_gemma":[0.037276786,0.9340601,0.0044181705,0.0045121,0.00070211635,0.014330805,0.0029399293,0.000053648728,0.0017063186],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.96934724,0.013396242,0.009443437,0.00087549206,0.0061978186,0.0007397652],"domain_scores_gemma":[0.89494693,0.0699967,0.010224274,0.0020384537,0.021317836,0.0014757528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.036561143,0.0011344154,0.003150389,0.015696855,0.0021121746,0.0051667085,0.0020146756,0.0034621863,0.015138191],"category_scores_gemma":[0.10647418,0.0012895598,0.004802295,0.014969182,0.0015432474,0.00430606,0.0048394236,0.0016915214,0.0022016377],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034051118,0.00010075873,0.0024568872,0.82584906,0.0016845317,0.00031319767,0.0040155766,0.00012850297,0.00036587354,0.0013595193,0.026762,0.13662364],"study_design_scores_gemma":[0.00007766515,0.00015015877,0.0028002486,0.9424033,0.0016357016,0.000253208,0.0015243042,0.000040046056,0.00011595471,0.0002124956,0.050765064,0.000021912228],"about_ca_topic_score_codex":0.009423412,"about_ca_topic_score_gemma":0.017223727,"teacher_disagreement_score":0.036561143,"about_ca_system_score_codex":0.0064029805,"about_ca_system_score_gemma":0.02778922,"threshold_uncertainty_score":0.19335616},"labels":[],"label_agreement":null},{"id":"W4393005622","doi":"10.1136/ejhpharm-2024-eahp.183","title":"4CPS-079 Indirect comparison of il-13 inhibitors plus topical corticosteroids in moderate to severe atopic dermatitis","year":2024,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Dupilumab; Placebo; Corticosteroid; Internal medicine; Clinical endpoint; Gastroenterology; Randomized controlled trial; Dermatology","score_opus":0.05583459261996076,"score_gpt":0.4134032319752196,"score_spread":0.35756863935525884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393005622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5859678,0.32887828,0.0041055456,0.0023436504,0.005382282,0.02097685,0.024576748,0.00033080712,0.02743796],"genre_scores_gemma":[0.9342143,0.04439543,0.0035577288,0.0010871585,0.0010344561,0.0061689746,0.0042546364,0.00003083256,0.0052563935],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99187976,0.006072784,0.00093284756,0.00030270487,0.0006501057,0.00016186993],"domain_scores_gemma":[0.9960097,0.002449814,0.00077968906,0.00015742013,0.00036875994,0.00023448262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052078483,0.0009136891,0.0043537584,0.0017947492,0.00034447957,0.0015857929,0.0007823678,0.0013642638,0.025150985],"category_scores_gemma":[0.007657217,0.00035948947,0.008201486,0.0017526136,0.0006036723,0.00069655053,0.00079418306,0.0016054269,0.0010774394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79581714,0.0018883256,0.0017306284,0.067864604,0.059614725,0.0001479166,0.00011233086,0.0009415472,0.0026977235,0.0010373577,0.0021674219,0.065980345],"study_design_scores_gemma":[0.6868584,0.13417973,0.017222693,0.00896884,0.12740853,0.00034535132,0.00029274847,0.00133734,0.0018085444,0.0015525522,0.019937724,0.00008747139],"about_ca_topic_score_codex":0.002021023,"about_ca_topic_score_gemma":0.004095872,"teacher_disagreement_score":0.025150985,"about_ca_system_score_codex":0.0011476589,"about_ca_system_score_gemma":0.001971708,"threshold_uncertainty_score":0.08413845},"labels":[],"label_agreement":null},{"id":"W4393026380","doi":"10.1136/ejhpharm-2024-eahp.245","title":"4CPS-141 Real-life impact of including montelukast as premedication on the incidence of infusion-related reactions to isatuximab and description of risk factors","year":2024,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leslie Dan Faculty of Pharmacy, University of Toronto; University of Waterloo","keywords":"Discontinuation; Tolerability; Medicine; Regimen; Placebo; Premedication; Odds ratio; Adverse effect; Number needed to treat; Internal medicine; Confidence interval; Relative risk; Anesthesia","score_opus":0.1080169857880549,"score_gpt":0.44373312146846533,"score_spread":0.3357161356804104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393026380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806307,0.00351258,0.0005882509,0.0007391698,0.00012781688,0.0003213708,0.0083631445,0.000088985646,0.005628058],"genre_scores_gemma":[0.99288166,0.0009235457,0.00072349526,0.00030647396,0.00018117196,0.00020746185,0.0033545385,0.00001756033,0.0014040564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991566,0.00034792977,0.00014026691,0.00009028149,0.000166909,0.00009802982],"domain_scores_gemma":[0.9961371,0.0007352934,0.0018106329,0.00019947444,0.00050674874,0.0006106939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012822144,0.00018241757,0.00033877397,0.0004463394,0.00024501787,0.00067133317,0.00023129885,0.00041127115,0.00975364],"category_scores_gemma":[0.0025128927,0.00010989312,0.0008239901,0.000645876,0.00017100187,0.00025146548,0.00033779177,0.0004358526,0.0014071595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015759315,0.0012605654,0.88130116,0.0009840211,0.00046002763,0.00094825885,0.000187406,0.00064275466,0.0023697421,0.0001832539,0.011927512,0.083975926],"study_design_scores_gemma":[0.00046865753,0.0071252314,0.97752255,0.00028159958,0.00027411082,0.002029744,0.00020858124,0.0006385137,0.0013395742,0.00009277078,0.009995801,0.00002272815],"about_ca_topic_score_codex":0.0017679747,"about_ca_topic_score_gemma":0.0013706823,"teacher_disagreement_score":0.00975364,"about_ca_system_score_codex":0.000642361,"about_ca_system_score_gemma":0.0011726521,"threshold_uncertainty_score":0.032629192},"labels":[],"label_agreement":null}]}